{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:03:13Z","timestamp":1789588993407,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ab.2025.115779","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T15:09:04Z","timestamp":1737299344000},"page":"115779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide)"],"prefix":"10.1016","volume":"700","author":[{"given":"Fadwa H.","family":"Edrees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3784-1332","authenticated-orcid":false,"given":"Maha M.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal B.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.ab.2025.115779_bib1","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.ab.2025.115779_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173748","article-title":"A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19","volume":"891","author":"Lokhande","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.ab.2025.115779_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5414\/CPP38387","article-title":"Nitazoxanide: pharmacokinetics and metabolism in man","volume":"38","author":"Broekhuysen","year":"2000","journal-title":"Int. J. Clin. Pharm. Ther."},{"issue":"1","key":"10.1016\/j.ab.2025.115779_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s13063-022-06533-0","article-title":"Favipiravir and\/or nitazoxanide: a randomized, double-blind, 2\u00d7 2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)","volume":"23","author":"Smith","year":"2022","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1556\/1326.2020.00828","article-title":"HPLC-UV method for quantification of favipiravir in pharmaceutical formulations","volume":"33","author":"Bulduk","year":"2021","journal-title":"Acta Chromatogr."},{"key":"10.1016\/j.ab.2025.115779_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106917","article-title":"A novel stability-indicating HPLC-DAD method for determination of favipiravir, a potential antiviral drug for COVID-19 treatment; application to degradation kinetic studies and in-vitro dissolution profiling","volume":"172","author":"Marzouk","year":"2022","journal-title":"Microchem. J."},{"issue":"4","key":"10.1016\/j.ab.2025.115779_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4155\/bio-2021-0219","article-title":"Determination of favipiravir in human plasma using homogeneous liquid\u2013liquid microextraction followed by HPLC\/UV","volume":"14","author":"Abdallah","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ab.2025.115779_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.106189","article-title":"Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens","volume":"165","author":"Mikhail","year":"2021","journal-title":"Microchem. J."},{"key":"10.1016\/j.ab.2025.115779_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.123087","article-title":"Menthol-assisted homogenous liquid-liquid microextraction for HPLC\/UV determination of favipiravir as an antiviral for COVID-19 in human plasma","volume":"1189","author":"Abdallah","year":"2022","journal-title":"J. Chromatogr. B"},{"issue":"7","key":"10.1016\/j.ab.2025.115779_bib11","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.3390\/molecules27072330","article-title":"Two green micellar HPLC and mathematically assisted UV spectroscopic methods for the simultaneous determination of molnupiravir and favipiravir as a novel combined COVID-19 antiviral regimen","volume":"27","author":"Sharaf","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib12","first-page":"57","article-title":"Comparison of HPLC and UV spectrophotometric methods for quantification of favipiravir in pharmaceutical formulations","volume":"20","author":"Bulduk","year":"2021","journal-title":"Iran. J. Pharm. Res. IJPR"},{"issue":"6","key":"10.1016\/j.ab.2025.115779_bib13","doi-asserted-by":"crossref","first-page":"e5365","DOI":"10.1002\/bmc.5365","article-title":"A gadolinium\u2010based magnetic ionic liquid for supramolecular dispersive liquid\u2013liquid microextraction followed by HPLC\/UV for the determination of favipiravir in human plasma","volume":"36","author":"Abdallah","year":"2022","journal-title":"Biomed. Chromatogr."},{"issue":"10","key":"10.1016\/j.ab.2025.115779_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/separations9100303","article-title":"Development and validation of HPLC-DAD method for the determination of favipiravir and studying the impact of vitamin C on the pharmacokinetics of COVID-19 antiviral drug favipiravir","volume":"9","author":"Hailat","year":"2022","journal-title":"Separations"},{"issue":"13","key":"10.1016\/j.ab.2025.115779_bib15","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.3390\/molecules26133789","article-title":"Development and validation of a method for quantification of favipiravir as COVID-19 management in spiked human plasma","volume":"26","author":"Hailat","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ab.2025.115779_bib16","article-title":"Fabric phase sorptive extraction-gas chromatography-mass spectrometry for the determination of favipiravir in biological and forensic samples","volume":"6","author":"Jain","year":"2023","journal-title":"Adv. Sample Prep."},{"key":"10.1016\/j.ab.2025.115779_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.microc.2021.107101","article-title":"Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs \u2018Remdesivir and Favipiravir\u2019: green assessment with application to pharmaceutical formulations and human plasma","volume":"174","author":"Noureldeen","year":"2022","journal-title":"Microchem. J."},{"key":"10.1016\/j.ab.2025.115779_bib18","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1002\/jssc.202200178","article-title":"Highly sensitive high\u2010performance thin\u2010layer chromatography method for the simultaneous determination of Molnupiravir, Favipiravir, and Ritonavir in pure forms and pharmaceutical formulations","volume":"45","author":"Saraya","year":"2022","journal-title":"J. Separ. Sci."},{"issue":"2","key":"10.1016\/j.ab.2025.115779_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28020529","article-title":"A non-instrumental green analytical method based on surfactant-assisted dispersive liquid\u2013liquid microextraction\u2013thin-layer chromatography\u2013smartphone-based digital image colorimetry(SA-DLLME-TLC-SDIC) for determining favipiravir in biological samples","volume":"28","author":"Jain","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.ab.2025.115779_bib20","first-page":"43","article-title":"Simultaneous RP-HPLC estimation of nitazoxanide and ofloxacin in tablet dosage forms","volume":"2","author":"Kumar","year":"2009","journal-title":"Asian J. Res. Chem."},{"issue":"1","key":"10.1016\/j.ab.2025.115779_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0250-474X.89763","article-title":"RP-HPLC method for simultaneous estimation of nitazoxanide and ofloxacin in tablets","volume":"73","author":"Sharma","year":"2011","journal-title":"Indian J. Pharmaceut. Sci."},{"issue":"4","key":"10.1016\/j.ab.2025.115779_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4103\/0250-474X.44600","article-title":"Simultaneous RPHPLC determination of nitazoxanide and ofloxacin in combined tablet dosage form","volume":"70","author":"Kalta","year":"2008","journal-title":"Indian J. Pharmaceut. Sci."},{"issue":"9","key":"10.1016\/j.ab.2025.115779_bib26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/chromsci\/bmt163","article-title":"Validated stability indicating RP-HPLC for quantitation of nitazoxanide in presence of its alkaline degradation products and their characterization by HPLC-tandem mass spectrometry","volume":"52","author":"Hegazy","year":"2014","journal-title":"J. Chromatogr. Sci."},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib27","first-page":"1140","article-title":"RP HPLC Method for estimation of nitazoxanide in oral suspension formulation","volume":"4","author":"Patel","year":"2012","journal-title":"Der Pharma Chem."},{"issue":"7\u20138","key":"10.1016\/j.ab.2025.115779_bib28","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1365\/s10337-007-0386-4","article-title":"A validated stability indicating RP-LC method for nitazoxanide, a new antiparasitic compound","volume":"66","author":"Jadhav","year":"2007","journal-title":"Chromatographia"},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/1573412910666140506225012","article-title":"A validated high performance liquid chromatographic (HPLC) assay for nitazoxanide in bulk and in pharmaceutical formulations","volume":"10","author":"A Saleh","year":"2014","journal-title":"Curr. Pharmaceut. Anal."},{"issue":"1","key":"10.1016\/j.ab.2025.115779_bib30","first-page":"29","article-title":"Stability indicating validated HPLC method for simultaneous quantification of nitazoxanide and ofloxacin in pharmaceutical dosage form","volume":"37","author":"Rakibe","year":"2018","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.ab.2025.115779_bib31","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.arabjc.2012.07.009","article-title":"Simultaneous determination of Nitazoxanide and Ofloxacin in pharmaceutical preparations using UV-spectrophotometric and high performance thin layer chromatography methods","volume":"10","author":"Sharma","year":"2017","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ab.2025.115779_bib32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1365\/s10337-007-0515-0","article-title":"Stability-indicating LC Determination of Nitazoxanide in bulk drug and in pharmaceutical dosage form","volume":"67","author":"Rane","year":"2008","journal-title":"Chromatographia"},{"issue":"2","key":"10.1016\/j.ab.2025.115779_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpha.2011.11.004","article-title":"Validated stability indicating methods for determination of nitazoxanide in presence of its degradation products","volume":"2","author":"Ali","year":"2012","journal-title":"J. Pharm. Anal."},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/10826070903526196","article-title":"Stability-indicating CZE method and stress degradation studies of nitazoxanide","volume":"33","author":"Malesuik","year":"2010","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"issue":"5","key":"10.1016\/j.ab.2025.115779_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4155\/bio-2018-0191","article-title":"Determination of sofosbuvir with two co-administered drugs; Paracetamol and DL-methionine by two chromatographic methods. Application to a pharmacokinetic study","volume":"11","author":"Fares","year":"2019","journal-title":"Bioanalysis"},{"issue":"9","key":"10.1016\/j.ab.2025.115779_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4598","article-title":"Different stability-indicating chromatographic methods for specific determination of paracetamol, dantrolene sodium, their toxic impurities and degradation products","volume":"33","author":"Abdelwahab","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"5","key":"10.1016\/j.ab.2025.115779_bib37","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jaoac\/94.5.1427","article-title":"Simultaneous determination of diloxanide furoate and metronidazole in presence of diloxanide furoate degradation products","volume":"94","author":"Abbas","year":"2011","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.ab.2025.115779_bib50","doi-asserted-by":"crossref","unstructured":"N.S. Abdelwahab, A.B. Ahmed, M.A. Omar, S.M. Derayea, M.M. Abdelrahman, Green chromatographic methods for simultaneous determination of quetiapine and the co-administrated paroxetine in rat plasma with application to pharmacokinetic study, Microchem. J. 152 (2020) 104317.","DOI":"10.1016\/j.microc.2019.104317"},{"key":"10.1016\/j.ab.2025.115779_bib38","first-page":"1","article-title":"Comparative preclinical pharmacokinetics and disposition of favipiravir following pulmonary and oral administration as potential adjunct therapy against airborne RNA viruses","author":"Devireddy","year":"2024","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"2","key":"10.1016\/j.ab.2025.115779_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jchromb.2008.09.017","article-title":"Liquid chromatography\u2013tandem mass spectrometry analysis of nitazoxanide and its major metabolites in goat","volume":"875","author":"Zhao","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ab.2025.115779_bib39","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cpdd.1402","article-title":"Pharmacokinetics of nitazoxanide dry suspensions after single oral doses in healthy subjects: Food effects evaluation and bioequivalence study","volume":"13","author":"Zhang","year":"2024","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"7","key":"10.1016\/j.ab.2025.115779_bib40","first-page":"17","article-title":"Pharmacological strategies for COVID-19-A review of the most promising repurposed antiviral drugs","volume":"21","author":"Chopra","year":"2021","journal-title":"Infect. Disord. Targets (Formerly Curr. Drug Targets-Infectious Disord."},{"key":"10.1016\/j.ab.2025.115779_bib41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ab.2025.115779_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2021.100820","article-title":"Thermodynamic properties of active pharmaceutical ingredients that are of interest in COVID-19","volume":"37","author":"Nagar","year":"2022","journal-title":"Chem. Data Collect."},{"issue":"7","key":"10.1016\/j.ab.2025.115779_bib43","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1021\/acs.jced.0c00254","article-title":"Solubility determination of nitazoxanide in twelve organic solvents from T= 273.15 to 313.15 K","volume":"65","author":"Zhang","year":"2020","journal-title":"J. Chem. Eng. Data"},{"key":"10.1016\/j.ab.2025.115779_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00044-016-1749-x","article-title":"Physicochemical characterization of two new Nitazoxanide analogs with antiparasitic activity","volume":"26","author":"Valladares-M\u00e9ndez","year":"2017","journal-title":"Med. Chem. Res."},{"issue":"1","key":"10.1016\/j.ab.2025.115779_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1573409911666150414145937","article-title":"Antiprotozoal nitazoxanide derivatives: synthesis, bioassays and QSAR study combined with docking for mechanistic insight","volume":"11","author":"Scior","year":"2015","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"10.1016\/j.ab.2025.115779_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jpba.2018.12.030","article-title":"Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?","volume":"165","author":"Kaza","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"8","key":"10.1016\/j.ab.2025.115779_bib47","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4155\/bio.12.41","article-title":"Development of a method by UPLC\u2013MS\/MS for the quantification of tizoxanide in human plasma and its pharmacokinetic application","volume":"4","author":"Marcel\u00edn-Jim\u00e9nez","year":"2012","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.ab.2025.115779_bib48","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/cpt.1909","article-title":"Prioritization of anti\u2010SARS\u2010Cov\u20102 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics","volume":"108","author":"Arshad","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ab.2025.115779_bib49","article-title":"United States pharmacopeia and national formulary (USP 37\u2013NF 32)","year":"2014","journal-title":"Rockville, MD US Pharmacop"},{"issue":"3","key":"10.1016\/j.ab.2025.115779_bib23","article-title":"RP-HPLC determination of nitazoxanide in bulk and different tablet formulations","volume":"3","author":"Jadhav","year":"2008","journal-title":"Eurasian J. Anal. Chem."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269725000168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269725000168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:00:28Z","timestamp":1739422828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269725000168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"alternative-id":["S0003269725000168"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2025.115779","relation":{},"ISSN":["0003-2697"],"issn-type":[{"value":"0003-2697","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide)","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2025.115779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115779"}}